The payer will use Evolent oncology offerings for its Centene and WellCare Medicare Advantage programs, according to a March 29 Evolent news release.
Centene finalized its sale of Magellan Specialty Health to Evolent in January. Centene announced the sale in November and said it and Evolent would launch a multiyear partnership upon the closing of the deal. Centene said it will continue and expand its relationship with Magellan Specialty Health as well as its ongoing expansion of Evolent’s oncology and end-of-life services.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.